Manchester, England, 11th February 2009 – F2G Limited, the Manchester UK based antifungal drug discovery and development company, today announced the appointment of Dr Tony Kennedy as Chief Scientific and Development Officer. In this capacity, Dr Kennedy will be responsible for the progression of F2G’s novel antifungal portfolio from discovery through development and the consolidation of the F2G development function.
Prior to joining F2G, Dr Kennedy led a number of anti-infective global development teams in Roche and SmithKline Beecham including the Roche-Gilead Tamiflu flu antiviral global team which advanced the molecule from discovery to registration in just over 3 years. Tony was then appointed as Roche Global Head of Project Management and served as a member of Roche’s Strategic Marketing Management Team and its Development Committee before being recruited to lead the Development Functions at UK Biotechs Trigen and Vantia.
Dr Kennedy commented “I am delighted to be joining F2G and working with the
outstanding team who have discovered a completely new class of antifungal agents with outstanding efficacy in preclinical efficacy models. These agents have the potential to address the high unmet medical needs in invasive fungal disease. I look forward to expediting the progression of our leads to clinical study and patient trials.”
The F2G Management Team is consolidated by the promotion of Dr Mike Birch, VP Operations, to the position of Chief Operating Officer. Dr Birch has a strong background expertise in antifungal research and has successfully discharged management roles of increasing responsibility for the company prior to his new appointment.
Dr Lloyd Payne, F2G’s Chief Scientific Officer, is leaving the company to pursue new career opportunities but will remain a consultant to F2G Ltd. Commenting on the changes, Shane Kelly, Chief Executive said “F2G is now poised to advance its lead antifungal assets into clinical development and we are restructuring the management team to equip ourselves for the challenges ahead. We are delighted to welcome Tony to our world-class team. He has extensive drug development experience and a successful track record of fast tracking projects through development. I am confident that his expertise will accelerate the development of our compounds.
Mike Birch, our new COO, has played a pivotal role in the development of the company and in building its strong relationships with the antifungal community both within Pharma and the clinic which will serve us well in the period ahead.
I would like to thank Dr Lloyd Payne for serving the company with distinction as CSO. The company wishes him well in his future career.”
About F2G Ltd:
F2G Ltd is dedicated to the discovery and development of new and clinically superior drug classes to treat life-threatening systemic fungal infections in at-risk patient populations. The antifungal market is currently estimated at over five and a half billion dollars annually and is growing steadily year on year. Market growth is expected to increase with the emergence of new
clinical indications in allergies and asthma.
For more information visit www.f2g.com
Chief Executive Officer
Tel: (+44) 0161 785 1271
Fax: (+44) 0161 785 1273